EcoDrugPlus

Cyclin Dependent Kinase 9

Ensembl ID : ENSG00000136807
Gene: CDK9
Gene Synonyms: C-2K,CDC2L4,PITALRE,TAK
7 APIs:
33 Enzyme and pathways 7 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSG00000173198
Gene: CYSLTR1
Gene Synonyms: CYSLT(1),CYSLT1,CYSLT1R
4 APIs:
16 Enzyme and pathways 7 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytidine Deaminase

Ensembl ID : ENSG00000158825
Gene: CDA
Gene Synonyms: CDD
1 APIs:
7 Enzyme and pathways 7 Cross references
232 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 11 Subfamily B Member 1

Ensembl ID : ENSG00000160882
Gene: CYP11B1
Gene Synonyms: CPN1,CYP11B,FHI,P450C11
2 APIs:
13 Enzyme and pathways 8 Cross references
40 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSG00000148795
Gene: CYP17A1
Gene Synonyms: CPT7,CYP17,P450C17,S17AH
4 APIs:
10 Enzyme and pathways 8 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSG00000137869
Gene: CYP19A1
Gene Synonyms: ARO,ARO1,AROMATASE,CPV1,CYAR,CYP19,P-450AROM
5 APIs:
13 Enzyme and pathways 8 Cross references
319 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSG00000095596
Gene: CYP26A1
Gene Synonyms: CP26,CYP26,P450RAI,P450RAI1
1 APIs:
9 Enzyme and pathways 7 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 4

Ensembl ID : ENSG00000160868
Gene: CYP3A4
Gene Synonyms: CYP3A3
3 APIs:
15 Enzyme and pathways 8 Cross references
638 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 43

Ensembl ID : ENSG00000021461
Gene: CYP3A43
Gene Synonyms:
2 APIs:
6 Enzyme and pathways 7 Cross references
652 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 5

Ensembl ID : ENSG00000106258
Gene: CYP3A5
Gene Synonyms: CP35,P450PCN3,PCN3
2 APIs:
6 Enzyme and pathways 9 Cross references
643 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 7

Ensembl ID : ENSG00000160870
Gene: CYP3A7
Gene Synonyms: CP37,P450-HFLA
2 APIs:
5 Enzyme and pathways 7 Cross references
646 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSG00000036530
Gene: CYP46A1
Gene Synonyms: CYP46
1 APIs:
10 Enzyme and pathways 7 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).